American Capital Management Inc. Buys New Position in Neogen Corporation $NEOG

American Capital Management Inc. bought a new stake in Neogen Corporation (NASDAQ:NEOG - Free Report) during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm bought 133,457 shares of the company's stock, valued at approximately $1,200,000. American Capital Management Inc. owned about 0.06% of Neogen as of its most recent SEC filing.

Several other institutional investors also recently added to or reduced their stakes in the business. UMB Bank n.a. raised its stake in Neogen by 238.2% during the 4th quarter. UMB Bank n.a. now owns 6,422 shares of the company's stock valued at $45,000 after purchasing an additional 4,523 shares during the last quarter. Hantz Financial Services Inc. grew its position in Neogen by 816.9% in the 4th quarter. Hantz Financial Services Inc. now owns 7,592 shares of the company's stock worth $53,000 after purchasing an additional 6,764 shares during the last quarter. Northwestern Mutual Wealth Management Co. grew its position in Neogen by 3,158.4% in the 4th quarter. Northwestern Mutual Wealth Management Co. now owns 8,309 shares of the company's stock worth $58,000 after purchasing an additional 8,054 shares during the last quarter. Los Angeles Capital Management LLC bought a new position in shares of Neogen during the 4th quarter worth about $65,000. Finally, Merit Financial Group LLC bought a new position in shares of Neogen during the 4th quarter worth about $71,000. 96.73% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

NEOG has been the topic of a number of recent research reports. Wall Street Zen raised Neogen from a "hold" rating to a "buy" rating in a research report on Saturday, May 9th. Piper Sandler raised Neogen from a "neutral" rating to an "overweight" rating and upped their price target for the company from $13.00 to $14.00 in a report on Wednesday. Finally, Weiss Ratings upgraded Neogen from a "sell (e+)" rating to a "sell (d-)" rating in a research report on Friday, August 7th. Three investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the stock presently has a consensus rating of "Hold" and a consensus target price of $12.00.

Trending Headlines about Neogen

Here are the key news stories impacting Neogen this week:

• Positive Sentiment: Piper Sandler upgraded Neogen on new management. The brokerage’s improved view suggests investors may expect management changes to improve execution, profitability, or growth. Neogen upgraded at Piper Sandler on new management
• Positive Sentiment: Zacks Research raised several future EPS forecasts. Estimates increased for the second and third quarters of fiscal 2027, the fourth quarter of fiscal 2027, and the third and fourth quarters of fiscal 2028. The full-year fiscal 2028 forecast also rose to $0.29 per share from $0.28, indicating modestly better expected earnings momentum. The current-year consensus remains $0.25 per share.
• Positive Sentiment: Neogen is receiving attention from value-oriented investors. A Zacks comparison of Neogen and Perrigo highlights investor interest in the medical-products sector and could increase visibility for NEOG among investors seeking a relatively attractive valuation. PRGO or NEOG: Which Is the Better Value Stock Right Now?
• Neutral Sentiment: Analysts’ price target is near the recent trading level. The reported consensus target of $11.67 suggests limited near-term upside based on that estimate, although targets can change following the Piper Sandler upgrade. Analysts Set Neogen Corporation PT at $11.67
• Neutral Sentiment: Short-interest data provides no meaningful signal. The report lists zero shares sold short and a zero-day short ratio, figures that appear anomalous and do not indicate either significant short-covering potential or notable bearish positioning.
• Negative Sentiment: Not all forecasts improved. Zacks lowered its fiscal first-quarter 2028 EPS estimate to $0.05 from $0.06, signaling that the earnings outlook remains uneven despite the broader upward revisions.

Neogen Price Performance

Neogen stock opened at $11.70 on Thursday. The business has a 50 day simple moving average of $10.37 and a 200 day simple moving average of $9.85. The company has a debt-to-equity ratio of 0.38, a current ratio of 3.82 and a quick ratio of 2.91. The company has a market capitalization of $2.55 billion, a PE ratio of -390.00, a price-to-earnings-growth ratio of 4.59 and a beta of 1.77. Neogen Corporation has a one year low of $4.90 and a one year high of $12.85.

Neogen (NASDAQ:NEOG - Get Free Report) last announced its quarterly earnings results on Thursday, July 30th. The company reported $0.09 earnings per share for the quarter, beating analysts' consensus estimates of $0.06 by $0.03. The firm had revenue of $225.30 million for the quarter, compared to analysts' expectations of $212.35 million. Neogen had a positive return on equity of 2.78% and a negative net margin of 0.91%.The business's revenue was down .1% compared to the same quarter last year. During the same period in the prior year, the business posted ($2.82) earnings per share. On average, sell-side analysts forecast that Neogen Corporation will post 0.25 EPS for the current fiscal year.

Neogen Profile

Neogen Corporation is a global provider of food and animal safety products, offering a broad portfolio of diagnostic and testing solutions. Headquartered in Lansing, Michigan, the company develops and manufactures tests designed to detect foodborne pathogens, allergens and toxins in food, beverage and environmental samples. Since its founding in 1982, Neogen has focused on delivering rapid, accurate and user‐friendly assays to food processors, grain handlers and quality laboratories around the world.

In the food safety arena, Neogen's product lineup includes immunoassay kits, molecular diagnostics and enrichment media for pathogens such as Salmonella, Listeria and E.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source